INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Be at least 18 years of age and able to give       │ Be at least 18 years of age and able to give       │     100 │
│ informed consent                                   │ informed consent                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Diagnosed with TB by criteria per Brazilian        │ Diagnosed with TB by criteria per Brazilian        │     100 │
│ Ministry of Health                                 │ Ministry of Health                                 │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a good clinical response to TB                │ Have a good clinical response to TB                │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Tolerating tuberculosis therapy containing         │ Tolerating tuberculosis therapy containing         │     100 │
│ rifampin for the 2 weeks prior to screening,except │ rifampin for the 2 weeks prior to screening,except │         │
│ for persons taking protease inhibitors at time of  │ for persons taking protease inhibitors at time of  │         │
│ diagnosis of TB.,. Subjects taking protease        │ diagnosis of TB.,. Subjects taking protease        │         │
│ inhibitors will be screened and initiate visit 1   │ inhibitors will be screened and initiate visit 1   │         │
│ within 3 days of starting TB medication            │ within 3 days of starting TB medication            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HIV positive with documentation present in source  │ HIV positive with documentation present in source  │     100 │
│ document                                           │ document                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a CD4 cell count greater than 50 cells/mm3if  │ Have a CD4 cell count greater than 50 cells/mm3if  │     100 │
│ not taking ART. Persons with cd4 \< 50 may be      │ not taking ART. Persons with cd4 < 50 may be       │         │
│ enrolled, if it is felt that in the best interest  │ enrolled, if it is felt that in the best interest  │         │
│ of the patient, that enrollment in the study will  │ of the patient, that enrollment in the study will  │         │
│ allow for quicker initiation of antiretroviral     │ allow for quicker initiation of antiretroviral     │         │
│ therapy than referral to another treatment center  │ therapy than referral to another treatment center  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Non-compliance with DOTPlus. Alternatively DOT can │ Non-compliance with DOTPlus. Alternatively DOT can │     100 │
│ be done by telephoning patient on a daily basis 5  │ be done by telephoning patient on a daily basis 5  │         │
│ times a week and having patient annotate taking    │ times a week and having patient annotate taking    │         │
│ drug in a log which would be reviewed by clinic    │ drug in a log which would be reviewed by clinic    │         │
│ staff                                              │ staff                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ History of being treated for tuberculosis in the   │ History of being treated for tuberculosis in the   │     100 │
│ prior 2 years unless there is DST, including PCR   │ prior 2 years unless there is DST, including PCR   │         │
│ testing, showing sensitivity to rifamycin          │ testing, showing sensitivity to rifamycin          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Known hypersensitivity to rifampin or rifabutin    │ Known hypersensitivity to rifampin or rifabutin    │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Liver enzymes greater than 2 times ULN             │ Liver enzymes greater than 2 times ULN             │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Bilirubin greater than 2 times ULN                 │ Bilirubin greater than 2 times ULN                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Serum creatinine greater than 3 times ULN          │ Serum creatinine greater than 3 times ULN          │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin less than 7.0 gms even if receiving     │ Hemoglobin less than 7.0 gms even if receiving     │     100 │
│ erythropoietin                                     │ erythropoietin                                     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absolute neutrophil count less than 750 cells/mm3  │ Absolute neutrophil count less than 750 cells/mm3  │     100 │
│ even if receiving G-CSF                            │ even if receiving G-CSF                            │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fasting triglycerides greater than 400 mg/dL       │ Fasting triglycerides greater than 400 mg/dL       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ GI intolerance of tuberculosis medications         │ GI intolerance of tuberculosis medications         │     100 │
│ requiring discontinuation of tuberculosis          │ requiring discontinuation of tuberculosis          │         │
│ medications                                        │ medications                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fasting glucose greater 150 mg/dL                  │ Fasting glucose greater 150 mg/dL                  │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant women                                     │ Pregnant women                                     │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Use of one of the prohibited medications           │ Use of one of the prohibited medications           │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition that the investigators feel could    │ Any condition that the investigators feel could    │     100 │
│ compromise the use of the current medication       │ compromise the use of the current medication       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a CD4 cell count of 50 cells/mm3or less       │ Have a CD4 cell count of 50 cells/mm3or less       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hepatitis B or C infection                         │ Hepatitis B or C infection                         │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Alcohol or illicit drug use, which in the          │ Alcohol or illicit drug use, which in the          │     100 │
│ investigators opinion may affect participation in  │ investigators opinion may affect participation in  │         │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Fasting cholesterol \> 1.6 upper limits of normal  │ Fasting cholesterol > 1.6 upper limits of normal   │      99 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤══════════════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                                │   Score │
╞═══════════════════════════════════╪══════════════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Serum creatinine greater than 3 times ULN    │      38 │
├───────────────────────────────────┼──────────────────────────────────────────────┼─────────┤
│ Must have maximum age of 65 Years │ Have a CD4 cell count of 50 cells/mm3or less │      42 │
╘═══════════════════════════════════╧══════════════════════════════════════════════╧═════════╛

Only CHIA has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Hepatitis B or C infection                         │ Antiretroviral naive                               │      35 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ HIV positive with documentation present in source  │ Taking Kaletra containing regimen with suppressed  │      41 │
│ document                                           │ viral load                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Any condition that the investigators feel could    │ Taking an NNRTI or integrase containing regimen    │      42 │
│ compromise the use of the current medication       │ without prior history of use of PI for more than 2 │         │
│                                                    │ weeks                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have a CD4 cell count greater than 50 cells/mm3if  │ Taking an NNRTI or integrase containing regimen    │      44 │
│ not taking ART. Persons with cd4 \< 50 may be      │ with prior exposure to PI greater than 2 weeks. It │         │
│ enrolled, if it is felt that in the best interest  │ must be clearly stated in the source document that │         │
│ of the patient, that enrollment in the study will  │ PI was switched to another agent for convenience   │         │
│ allow for quicker initiation of antiretroviral     │                                                    │         │
│ therapy than referral to another treatment center  │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Tolerating tuberculosis therapy containing         │ Taking another PI containing regimens with         │      45 │
│ rifampin for the 2 weeks prior to screening,except │ suppressed viral load. It must be clearly stated   │         │
│ for persons taking protease inhibitors at time of  │ in source document that if another PI was used for │         │
│ diagnosis of TB.,. Subjects taking protease        │ greater than 2 weeks the regimen was switched to   │         │
│ inhibitors will be screened and initiate visit 1   │ another agent for convenience. Subjects with prior │         │
│ within 3 days of starting TB medication            │ history of PI use may be enrolled, if there is a   │         │
│                                                    │ genotype showing no resistance to Kaletra Other    │         │
│                                                    │ Inclusion criteria                                 │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Levenshtein Ratio of Entire trial at once: 83
Average Levenshtein Ratio of individual lines: 86.64516129032258
OverAll Ratio: 84.82258064516128
